Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 10/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.40 |
| ▸ | CPB1 | P15086 | 2/20 | 0.40 |
| ▸ | TRHR | P34981 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10101283 | 0.88 | SCN9A (0.48) | SCN9AFPR2CPB2CPB1TRHR | |
| SCHEMBL14853085 | 0.79 | SCN9A (0.42) | SCN9AFPR2CPB2CPB1TRHR | |
| SCHEMBL5500074 | 0.77 | CPB2 (0.47) | SCN9ACPB2CPB1 | |
| SCHEMBL12980124 | 0.77 | SCN9A (0.41) | SCN9AFPR2CPB2CPB1TRHR | |
| SCHEMBL14886285 | 0.77 | SCN9A (0.41) | SCN9AFPR2CPB2CPB1TRHR | |
| SCHEMBL689785 | 0.76 | CPB2 (0.45) | SCN9ACPB2CPB1TRHR | |
| SCHEMBL689786 | 0.76 | CPB2 (0.45) | SCN9ACPB2CPB1TRHR | |
| SCHEMBL19364688 | 0.75 | SCN9A (0.40) | SCN9AFPR2CPB2CPB1TRHR | |
| SCHEMBL888805 | 0.74 | SCN9A (0.43) | SCN9AFPR2CPB2CPB1TRHR | |
| Hydrochloric Acid SCHEMBL8843356 | 0.74 | CPB2 (0.44) | SCN9AFPR2CPB2CPB1TRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207345-B2 | Antitumor agents; use in combination with other drugs such as pentamidine | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-7915416-B2 | Tetrahydroquinolines | MERCK PATENT GMBH (DE) | 2011-03-29 | — | — | US | disclosed |
| US-20090030028-A1 | Tetrahydroquinolines | MERCK PATENT GMBH (DE) | 2009-01-29 | — | — | US | disclosed |
| US-20080200451-A1 | Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 | MERCK PATENT GMBH (DE) | 2008-08-21 | — | — | US | disclosed |
| US-20080194615-A1 | Antitumor agents; anticancer agents | MERCK PATENT GMBH (DE) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200451-A1 | Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 | KIF5A, KIF5C, KIF5B | SCN9A 2941/4885FPR2 4854/4885CPB2 4483/4885 |
| US-20090030028-A1 | Tetrahydroquinolines | RECQL, QTRT1, NRAS | SCN9A 3976/4885FPR2 1732/4885CPB2 4564/4885 |
| US-20080194615-A1 | Antitumor agents; anticancer agents | RB1, TP53, CCNT1 | SCN9A 4510/4885FPR2 4364/4885CPB2 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.